# Dexcom Inc: financial statements, quarterly

DXCM · Nasdaq · CIK 1093557 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dxcm.md) · [Financials](/companies/dxcm/financials.md) · [Filings](/companies/dxcm/filings.md) · [Insiders](/companies/dxcm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dxcm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [975](/filings/0001093557-24-000180.md) | [1,035 d](/filings/0001093557-26-000027.md) | [921](/filings/0001093557-25-000113.md) | [1,004](/filings/0001093557-25-000243.md) | [994](/filings/0001093557-25-000280.md) | [1,114 d](/filings/0001093557-26-000027.md) | [1,036](/filings/0001093557-26-000073.md) | [1,157](/filings/0001093557-26-000143.md) | [1,209](/filings/0001093557-25-000280.md) | [1,260 d](/filings/0001093557-26-000027.md) | [1,192](/filings/0001093557-26-000073.md) | [1,308](/filings/0001093557-26-000143.md) |
| Cost of revenue | $m | [352](/filings/0001093557-24-000180.md) | [378 d](/filings/0001093557-26-000027.md) | [359](/filings/0001093557-25-000113.md) | [378](/filings/0001093557-25-000243.md) | [400](/filings/0001093557-25-000280.md) | [458 d](/filings/0001093557-26-000027.md) | [447](/filings/0001093557-26-000073.md) | [468](/filings/0001093557-26-000143.md) | [478](/filings/0001093557-25-000280.md) | [467 d](/filings/0001093557-26-000027.md) | [442](/filings/0001093557-26-000073.md) | [478](/filings/0001093557-26-000143.md) |
| Gross profit | $m | [623](/filings/0001093557-24-000180.md) | [657 d](/filings/0001093557-26-000027.md) | [562](/filings/0001093557-25-000113.md) | [627](/filings/0001093557-25-000243.md) | [594](/filings/0001093557-25-000280.md) | [656 d](/filings/0001093557-26-000027.md) | [589](/filings/0001093557-26-000073.md) | [689](/filings/0001093557-26-000143.md) | [731](/filings/0001093557-25-000280.md) | [793 d](/filings/0001093557-26-000027.md) | [750](/filings/0001093557-26-000073.md) | [830](/filings/0001093557-26-000143.md) |
| Research and development | $m | [131](/filings/0001093557-24-000180.md) | [136 d](/filings/0001093557-26-000027.md) | [142](/filings/0001093557-25-000113.md) | [136](/filings/0001093557-25-000243.md) | [135](/filings/0001093557-25-000280.md) | [140 d](/filings/0001093557-26-000027.md) | [145](/filings/0001093557-26-000073.md) | [148](/filings/0001093557-26-000143.md) | [158](/filings/0001093557-25-000280.md) | [148 d](/filings/0001093557-26-000027.md) | [145](/filings/0001093557-26-000073.md) | [153](/filings/0001093557-26-000143.md) |
| Selling, general and administrative | $m | [286](/filings/0001093557-24-000180.md) | [304 d](/filings/0001093557-26-000027.md) | [319](/filings/0001093557-25-000113.md) | [333](/filings/0001093557-25-000243.md) | [306](/filings/0001093557-25-000280.md) | [327 d](/filings/0001093557-26-000027.md) | [310](/filings/0001093557-26-000073.md) | [328](/filings/0001093557-26-000143.md) | [331](/filings/0001093557-25-000280.md) | [322 d](/filings/0001093557-26-000027.md) | [350](/filings/0001093557-26-000073.md) | [359](/filings/0001093557-26-000143.md) |
| Operating income | $m | [206](/filings/0001093557-24-000180.md) | [217 d](/filings/0001093557-26-000027.md) | [101](/filings/0001093557-25-000113.md) | [158](/filings/0001093557-25-000243.md) | [152](/filings/0001093557-25-000280.md) | [189 d](/filings/0001093557-26-000027.md) | [134](/filings/0001093557-26-000073.md) | [213](/filings/0001093557-26-000143.md) | [243](/filings/0001093557-25-000280.md) | [323 d](/filings/0001093557-26-000027.md) | [255](/filings/0001093557-26-000073.md) | [318](/filings/0001093557-26-000143.md) |
| Interest expense | $m | [4.9](/filings/0001093557-23-000220.md) | [4.9 d](/filings/0001093557-24-000021.md) | [4.6](/filings/0001093557-24-000079.md) | [4.8](/filings/0001093557-25-000243.md) | [4.7](/filings/0001093557-25-000280.md) | [4.9 d](/filings/0001093557-26-000027.md) | [4.7](/filings/0001093557-26-000073.md) | [4.7](/filings/0001093557-26-000143.md) | [4.7](/filings/0001093557-25-000280.md) | [4.2 d](/filings/0001093557-26-000027.md) | [3.1](/filings/0001093557-26-000073.md) | [3.0](/filings/0001093557-26-000143.md) |
| Income tax | $m | [120](/filings/0001093557-24-000180.md) | [(10.1) d](/filings/0001093557-26-000027.md) | [(13.9)](/filings/0001093557-25-000113.md) | [44.3](/filings/0001093557-25-000243.md) | [42.8](/filings/0001093557-25-000280.md) | [59.6 d](/filings/0001093557-26-000027.md) | [48.9](/filings/0001093557-26-000073.md) | [61.3](/filings/0001093557-26-000143.md) | [68.5](/filings/0001093557-25-000280.md) | [73.4 d](/filings/0001093557-26-000027.md) | [70.0](/filings/0001093557-26-000073.md) | [68.4](/filings/0001093557-26-000143.md) |
| Net income | $m | [121](/filings/0001093557-24-000180.md) | [256 d](/filings/0001093557-26-000027.md) | [146](/filings/0001093557-25-000113.md) | [144](/filings/0001093557-25-000243.md) | [135](/filings/0001093557-25-000280.md) | [152 d](/filings/0001093557-26-000027.md) | [105](/filings/0001093557-26-000073.md) | [180](/filings/0001093557-26-000143.md) | [284](/filings/0001093557-25-000280.md) | [267 d](/filings/0001093557-26-000027.md) | [200](/filings/0001093557-26-000073.md) | [249](/filings/0001093557-26-000143.md) |
| Diluted EPS | $ per share | [0.29](/filings/0001093557-24-000180.md) | not reported | [0.36](/filings/0001093557-25-000113.md) | [0.35](/filings/0001093557-25-000243.md) | [0.34](/filings/0001093557-25-000280.md) | not reported | [0.27](/filings/0001093557-26-000073.md) | [0.45](/filings/0001093557-26-000143.md) | [0.70](/filings/0001093557-25-000280.md) | not reported | [0.51](/filings/0001093557-26-000073.md) | [0.64](/filings/0001093557-26-000143.md) |
| Basic EPS | $ per share | [0.31](/filings/0001093557-24-000180.md) | not reported | [0.38](/filings/0001093557-25-000113.md) | [0.36](/filings/0001093557-25-000243.md) | [0.34](/filings/0001093557-25-000280.md) | not reported | [0.27](/filings/0001093557-26-000073.md) | [0.46](/filings/0001093557-26-000143.md) | [0.73](/filings/0001093557-25-000280.md) | not reported | [0.52](/filings/0001093557-26-000073.md) | [0.65](/filings/0001093557-26-000143.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [644](/filings/0001093557-24-000180.md) | [566](/filings/0001093557-26-000027.md) | [851](/filings/0001093557-25-000113.md) | [939](/filings/0001093557-25-000243.md) | [621](/filings/0001093557-25-000280.md) | [606](/filings/0001093557-26-000027.md) | [905](/filings/0001093557-26-000073.md) | [1,159](/filings/0001093557-26-000143.md) | [1,836](/filings/0001093557-25-000280.md) | [918](/filings/0001093557-26-000143.md) | [1,118](/filings/0001093557-26-000073.md) | [1,105](/filings/0001093557-26-000143.md) |
| Current assets | $m | [4,698](/filings/0001093557-23-000220.md) | [4,426](/filings/0001093557-25-000036.md) | [4,621](/filings/0001093557-24-000079.md) | [4,848](/filings/0001093557-24-000144.md) | [4,263](/filings/0001093557-24-000180.md) | [4,301](/filings/0001093557-26-000027.md) | [4,554](/filings/0001093557-25-000113.md) | [5,030](/filings/0001093557-25-000243.md) | [5,220](/filings/0001093557-25-000280.md) | [4,033](/filings/0001093557-26-000143.md) | [4,332](/filings/0001093557-26-000073.md) | [4,087](/filings/0001093557-26-000143.md) |
| Total assets | $m | [6,596](/filings/0001093557-23-000220.md) | [6,265](/filings/0001093557-25-000036.md) | [6,482](/filings/0001093557-24-000079.md) | [6,799](/filings/0001093557-24-000144.md) | [6,354](/filings/0001093557-24-000180.md) | [6,485](/filings/0001093557-26-000027.md) | [6,752](/filings/0001093557-25-000113.md) | [7,327](/filings/0001093557-25-000243.md) | [7,500](/filings/0001093557-25-000280.md) | [6,340](/filings/0001093557-26-000143.md) | [6,633](/filings/0001093557-26-000073.md) | [6,455](/filings/0001093557-26-000143.md) |
| Current liabilities | $m | [1,679](/filings/0001093557-23-000220.md) | [1,556](/filings/0001093557-25-000036.md) | [1,594](/filings/0001093557-24-000079.md) | [1,722](/filings/0001093557-24-000144.md) | [1,735](/filings/0001093557-24-000180.md) | [2,932](/filings/0001093557-26-000027.md) | [3,037](/filings/0001093557-25-000113.md) | [3,309](/filings/0001093557-25-000243.md) | [3,336](/filings/0001093557-25-000280.md) | [2,143](/filings/0001093557-26-000143.md) | [2,224](/filings/0001093557-26-000073.md) | [2,358](/filings/0001093557-26-000143.md) |
| Total liabilities | $m | [4,328](/filings/0001093557-23-000220.md) | [4,196](/filings/0001093557-25-000036.md) | [4,235](/filings/0001093557-24-000079.md) | [4,365](/filings/0001093557-24-000144.md) | [4,375](/filings/0001093557-24-000180.md) | [4,382](/filings/0001093557-26-000027.md) | [4,485](/filings/0001093557-25-000113.md) | [4,754](/filings/0001093557-25-000243.md) | [4,774](/filings/0001093557-25-000280.md) | [3,594](/filings/0001093557-26-000143.md) | [3,676](/filings/0001093557-26-000073.md) | [3,834](/filings/0001093557-26-000143.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,268](/filings/0001093557-24-000180.md) | [2,069](/filings/0001093557-26-000027.md) | [2,247](/filings/0001093557-25-000243.md) | [2,434](/filings/0001093557-25-000280.md) | [1,979](/filings/0001093557-25-000280.md) | [2,103](/filings/0001093557-26-000143.md) | [2,267](/filings/0001093557-26-000143.md) | [2,573](/filings/0001093557-26-000143.md) | [2,726](/filings/0001093557-25-000280.md) | [2,746](/filings/0001093557-26-000143.md) | [2,957](/filings/0001093557-26-000143.md) | [2,621](/filings/0001093557-26-000143.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [269 d](/filings/0001093557-24-000180.md) | [134 d](/filings/0001093557-26-000027.md) | [209](/filings/0001093557-25-000113.md) | [279 d](/filings/0001093557-25-000243.md) | [200 d](/filings/0001093557-25-000280.md) | [301 d](/filings/0001093557-26-000027.md) | [184](/filings/0001093557-26-000073.md) | [303 d](/filings/0001093557-26-000143.md) | [660 d](/filings/0001093557-25-000280.md) | [294 d](/filings/0001093557-26-000027.md) | [526](/filings/0001093557-26-000073.md) | [269 d](/filings/0001093557-26-000143.md) |
| Capital expenditure | $m | [50.4 d](/filings/0001093557-24-000180.md) | [52.5 d](/filings/0001093557-26-000027.md) | [56.9](/filings/0001093557-25-000113.md) | [66.1 d](/filings/0001093557-25-000243.md) | [111 d](/filings/0001093557-25-000280.md) | [125 d](/filings/0001093557-26-000027.md) | [87.0](/filings/0001093557-26-000073.md) | [94.1 d](/filings/0001093557-26-000143.md) | [80.5 d](/filings/0001093557-25-000280.md) | [102 d](/filings/0001093557-26-000027.md) | [76.6](/filings/0001093557-26-000073.md) | [84.7 d](/filings/0001093557-26-000143.md) |
| Share repurchases | $m | [0.0 d](/filings/0001093557-24-000180.md) | [500 d](/filings/0001093557-26-000027.md) | not reported | not reported | [750 d](/filings/0001093557-25-000280.md) | [0.0 d](/filings/0001093557-26-000027.md) | not reported | not reported | [187 d](/filings/0001093557-25-000280.md) | [313 d](/filings/0001093557-26-000027.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [426](/filings/0001093557-23-000220.md) | [419](/filings/0001093557-24-000079.md) | [432](/filings/0001093557-24-000144.md) | [427](/filings/0001093557-24-000180.md) | [417](/filings/0001093557-25-000113.md) | [417](/filings/0001093557-25-000243.md) | [410](/filings/0001093557-25-000280.md) | [408](/filings/0001093557-26-000073.md) | [408](/filings/0001093557-26-000143.md) | [407](/filings/0001093557-25-000280.md) | [394](/filings/0001093557-26-000073.md) | [390](/filings/0001093557-26-000143.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 377,360,765 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001093557-26-000143.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.